secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verona Pharma plc (—)
CIK:        0001657312
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001104659-23-126869
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verona Pharma dismisses PwC, appoints EY as auditor subject to 2024 AGM vote
----------------------------------------------------------------------------

- Audit committee dismissed PwC on Dec 14, 2023; approved EY engagement for FY 2024 subject to shareholder appointment at 2024 AGM.
- No disagreements or reportable events between Verona and PwC during FY 2021-2022 and interim period through Dec 14, 2023.
- PwC's reports on FY 2022 and FY 2021 financial statements were unqualified, containing no adverse opinion or modification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657312/000110465923126869/0001104659-23-126869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657312/000110465923126869/tm2333000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer